Syncona's Purespring raises £80m in new financing

Oct 9, 2024 · (Alliance News) - Syncona Ltd on Wednesday announced it has committed GBP19.9 million in a series B financing of Purespring Therapeutics, which will b... 3 Oct 2024 …

CouponFollow Extension

£80
OFF

Syncona's Purespring Raises £80m In New Financing

6 days from now

Oct 9, 2024 · (Alliance News) - Syncona Ltd on Wednesday announced it has committed GBP19.9 million in a series B financing of Purespring Therapeutics, which will b... 3 Oct 2024 …

lse.co.uk

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

£80
OFF

Purespring Therapeutics Series B Financing – Company …

6 days from now

9 October 2024 Syncona Limited Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

ft.com

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024 · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$104711631
OFF

Series B - Purespring Therapeutics - 2024-10-09 - Crunchbase

6 days from now

Oct 9, 2024 · Purespring Therapeutics raised $104711631 on 2024-10-09 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …

crunchbase.com

$105
OFF

Purespring Secures $105m To Start Phase I/II Trial Of IgAN Gene …

6 days from now

Oct 9, 2024 · Purespring secures $105m to start Phase I/II trial of IgAN gene therapy. Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead …

clinicaltrialsarena.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

globenewswire.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million …

icheme.org

£80
OFF

Purespring Therapeutics Raises £80M In Series B Round To Launch …

6 days from now

Oct 9, 2024 · Purespring Therapeutics Raises £80M in Series B Round to Launch Kidney Disease Gene Therapy Trial ... Save for later NEW YORK – Purespring Therapeutics on Wednesday …

precisionmedicineonline.com

$105
OFF

Purespring Therapeutics Secures £80/$105M In Series B Funding …

6 days from now

Oct 9, 2024 · Purespring Therapeutics has raised £80/$105 million in a Series B financing round, led by Sofinnova Partners and featuring other prominent investors, to advance its gene …

ainvest.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

biospace.com

$105
OFF

Purespring Therapeutics Ltd.. (10/9/24). "Press Release: Purespring ...

6 days from now

Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in a Series B …

life-sciences-europe.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy …

businessupturn.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In Series B …

6 days from now

London, 7 October, 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 …

forbion.com

€96
OFF

Purespring Bags £80m To Transform Kidney Disease Treatment

6 days from now

Oct 21, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B …

european-biotechnology.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

businessinsider.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in …

tmcnet.com

$105
OFF

Purespring Therapeutics Raised A $105M Series B Earlier This Month …

6 days from now

Oct 24, 2024 · CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key preclinical data for the lead IgA …

biotechtv.com

FAQs about Syncona's Purespring raises £80m in new financing Coupon?

Who is purespring Therapeutics?

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in a Series B financing. ...

Does purespring therapeutics have a series B financing?

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona ...

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

What is purespring & how does it work?

Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. ...

When is purespring presenting Igan data for the first time?

Purespring will present its IgAN data publicly for the first time at the American Society of Nephrology (ASN) Kidney Week congress on October 26 in San Diego (abstract #SA-OR63). For further information, contact: Purespring: ICR Consilium ...

What will ps-002 funding mean for purespring?

The funds raised will allow us to bring our novel treatments to patients in the clinic.” The funds will filter to drugs throughout Purespring’s pipeline, including lead asset PS-002, which is being developed for IgA nephropathy, a disease caused by a build-up of immunoglobulin A in the kidneys. ...